Department of Defense September 13, 2010 – Federal Register Recent Federal Regulation Documents
Results 1 - 4 of 4
Privacy Act of 1974; System of Records
The Office of the Secretary of Defense proposes to delete a system of records notice from its existing inventory of record systems subject to the Privacy Act of 1974, (5 U.S.C. 552a), as amended.
Office of the Secretary: Notification of an Open Meeting of the National Defense University Board of Visitors (BOV)
The National Defense University (NDU), Designated Federal Officer, has scheduled a meeting of the Board of Visitors for November 4 and 5, 2010, in Washington, DC. The National Defense University Board of Visitors is a Federal Advisory Board. The Board meets twice a year in proceedings that are open to the public.
Office of the Secretary: Defense Science Board (DSB) Task Force on the Survivability of DoD Systems and Assets to Electromagnetic Pulse (EMP) and Other Nuclear Weapons Effects
Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense announces that the Defense Science Board (DSB) Task Force on the Survivability of DoD Systems and Assets to Electromagnetic Pulse (EMP) and other Nuclear Weapons Effects (hereafter referred to as the Task Force) will meet October 12-13, 2010 in Lorton, VA.
Intent To Grant Field of Use Exclusive License to U.S. Government-Owned Patents
In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 (a)(1)(i) and 404.7(b)(1)(i), announcement is made of the intent to grant a field of use exclusive, revocable license for the field of prevention and/or therapeutic treatment of vaccinia virus infections or other orthopoxvirus infections to the inventions claimed in U.S. Patent No. 6,451,309 entitled ``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued September 17, 2002, and U.S. Patent No. 6,620,412 entitled ``Prophylactic and Therapeutic Monoclonal Antibodies,'' issued September 16, 2003, which is a continuation of U.S. Patent No. 6,451,309, and related foreign patents and patent applications (PCT/ US2001/04520) to Biofactura, Inc., with its principal place of business at 9430 Key West Avenue, Suite 125, Rockville, MD 20850-6345.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
